Compare InMode Ltd (INMD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs 10X Genomics Inc — how do they compare? InMode Ltd trades at $14.16 (market cap $809.93M), while 10X Genomics Inc trades at $83.55 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 12.4× InMode Ltd's market cap, and 10X Genomics Inc is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 29 Days and 10X Genomics Inc for 92 Days on average.
| INMD | TXG | |
|---|---|---|
Market Cap | $809.93M | $10.07B |
Volume | 365,490 | 5,657,286 |
Sector | Health | Health |
52-Week High | $16.62 | $97.74 |
52-Week Low | $12.76 | $11.48 |
Typical Hold Time | 29 Days | 92 Days |
Enterprise Value | $313.27M | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.01, up 0.14% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 earnings of $0.35 per share, beating expectations, and maintains a strong gross profit margin of 76.52%. Recent news includes the launch of Morpheus8 Cool and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The outlook is mixed: valuation metrics like P/E of 11.63 and EV/EBITDA of 4.48 appear attractive, but declining net income and bearish technicals pose risks. Analyst consensus is divided with 45.45% buy ratings, highlighting potential upside from strategic developments against execution challenges.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
